Heliyon, 2022 · DOI: https://doi.org/10.1016/j.heliyon.2022.e11279 · Published: October 20, 2022
Spinal cord injury (SCI) can cause significant harm. Erxian Decoction (EXD) shows promise in treating SCI after surgery, but how it works is not well understood. This research uses computer analysis and lab tests to study how EXD might help with SCI. The study looks at how EXD affects the spinal cord in rats. The study found that EXD improves motor function, reduces swelling, and changes the levels of certain proteins in rats with SCI. It suggests that EXD may help by preventing cell death through the activation of a protein called Akt1.
EXD may serve as a promising therapeutic agent for spinal cord injury due to its ability to improve motor function and reduce spinal cord edema.
The study identifies a novel mechanism through which EXD attenuates apoptosis via the activation of Akt1 phosphorylation, providing insights into targeted SCI treatment.
The findings support the potential clinical application of EXD in postoperative treatment of spinal cord injury, highlighting its role in restoring behavioral function.